


**Product Name** : BAY1082439  
**Cat. No.** : PC-63437  
**CAS No.** : 1375469-38-7  
**Molecular Formula** : C<sub>25</sub>H<sub>30</sub>N<sub>6</sub>O<sub>5</sub>  
**Molecular Weight** : 494.228  
**Target** : PI3K  
**Solubility** : 10 mM in DMSO



## Biological Activity

BAY1082439 is a potent, highly selective, orally available **PI3K $\alpha$ / $\beta$**  inhibitor with IC<sub>50</sub> of 4.9 nM (PI3K $\alpha$ ), selectively inhibits both PI3K $\alpha$ , including mutated forms of PIK3CA, and PI3K $\beta$  in the PI3K/Akt/mTOR pathway.

BAY1082439 displays >1000-fold selectivity against mTOR kinase.

BAY1082439 induces tumor cell apoptosis and growth inhibition in PI3K-expressing and/or PTEN-driven tumor cells.

BAY1082439 is more effective than PI3K $\alpha$ - and/or PI3K $\beta$ -selective inhibitors in blocking PTEN-null prostate cancer cells.

BAY1082439 effectively inhibits *Pten*-null prostate cancer progression

## References

Ningshu Liu, et al. Abstract 2799: BAY 1082439, a highly selective and balanced PI3K $\alpha$ / $\beta$  inhibitor demonstrated potent activity in tumors with activated PI3K $\alpha$  and loss-of-function of PTEN. Abstract nr 2799. doi:1538-7445.AM2012-2799.

2. Yongkang Zou, et al. *Mol Cancer Ther.* 2018 Oct;17(10):2091-2099.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com